Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Net Income: 2009-2025

Historic Net Income for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to -$178.1 million.

  • Cytokinetics' Net Income fell 18.95% to -$178.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$602.1 million, marking a year-over-year decrease of 7.41%. This contributed to the annual value of -$573.9 million for FY2024, which is 9.43% down from last year.
  • Per Cytokinetics' latest filing, its Net Income stood at -$178.1 million for Q3 2025, which was down 47.96% from -$120.4 million recorded in Q2 2025.
  • Cytokinetics' 5-year Net Income high stood at -$13.7 million for Q2 2022, and its period low was -$178.1 million during Q3 2025.
  • In the last 3 years, Cytokinetics' Net Income had a median value of -$134.6 million in 2023 and averaged -$141.1 million.
  • Per our database at Business Quant, Cytokinetics' Net Income slumped by 6,173.01% in 2021 and then spiked by 76.76% in 2022.
  • Cytokinetics' Net Income (Quarterly) stood at -$25.9 million in 2021, then crashed by 417.27% to -$134.1 million in 2022, then dropped by 0.37% to -$134.6 million in 2023, then fell by 9.95% to -$148.0 million in 2024, then decreased by 18.95% to -$178.1 million in 2025.
  • Its last three reported values are -$178.1 million in Q3 2025, -$120.4 million for Q2 2025, and -$155.6 million during Q1 2025.